Bromday Battle Broadens: Ocular Drug Infection Risks, Fill Size Limits Will Get FDA Cmte. Scrutiny
Executive Summary
The Dermatologic and Ophthalmic Drugs Advisory Committee will meet Feb. 27 to discuss issues at the heart of Bromday marketer ISTA Pharmaceuticals’ dispute with the Center for Drug Evaluation and Research over post-operative use of a single-bottle ophthalmic agent in both eyes.
You may also be interested in...
CDER's Rejection Of Larger Bromday Bottle Rests On Hypothetical Risk, ISTA Says
FDA drug reviewers’ rejection of a larger fill size for ISTA Pharmaceuticals’ ocular agent Bromday (bromfenac ophthalmic solution 0.09%) was based on a hypothetical risk from a use that is contrary to product labeling, the company says.
Safety Concerns Over Larger Bottle For ISTA's Bromday Could Impact Other Eye Drugs
FDA's Center for Drug Evaluation and Research refused to approve ISTA's sNDA for a larger fill size of the topical non-steroidal anti-inflammatory because it does not believe a single bottle should be used to dose drug in both eyes.
Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: